Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
NEW YORK, Sept. 23, 2016 -- The Nasdaq Stock Market announced today that it will delist the common stock of BIND Therapeutics, Inc. BIND Therapeutics, Inc.’s stock was suspended on August 01, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock and warrant of InterCloud Systems, Inc. InterCloud Systems, Inc’s common stock and warrant were suspended on August 31, 2016 and have not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock of Echo Therapeutics, Inc. Echo Therapeutics, Inc.’s stock was suspended on July 12, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock, warrant, unit and right of 1347 Capital Corp. 1347 Capital Corp.’s common stock, warrant, unit and right were suspended on July 12, 2016 and have not traded on Nasdaq since that time.
Finally, Nasdaq announced that it will delist the common stock of EPIRUS Biopharmaceuticals, Inc. EPIRUS Biopharmaceuticals, Inc.’s stock was suspended on August 04, 2016 and has not traded on Nasdaq since that time.
Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting for each of these companies. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delistings and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: http://www.cchwallstreet.com/NasdaqTools/bookmark.asp?id=nasdaq-rule_5800&manual=/nasdaq/main/nasdaq-equityrules/.
NDAQO
